Clinical Trial: CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449923) titled 'CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME' on Feb. 27.

Brief Summary: This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Study Start Date: Feb. 09

Study Type: INTERVENTIONAL

Condition: Diabetic Macular Edema DME Diabetic Macular Edema (DME)

Intervention: DRUG: EYP-1901

Intravitreal Injection

DRUG: Aflibercept (2.0 mg)

Intravitreal Injection

Recruitment Status: RECRUITING

Sponsor: EyePoint Pharmaceuticals, Inc.

Disclaimer: Curated by HT Syndication....